B
Bull
Bull · 25%JANX
$60.28
Scenario price
$17.130
-0.050 (-0.29%)At close
Loading chart…
- High
- 17.490
- Open
- 17.130
- VWAP
- 17.15
- Volume
- 614.66K
- Mkt Cap
- 2.09B
- Low
- 16.840
- Amount
- 10.54M
- EV/EBITDA, TTM
- -45.18
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
AI analysis of Janux Therapeutics Inc (JANX)
BuyJanux Therapeutics Inc is a good buy right now due to its recent price increase of 8.62% over the last five days and a strong RSI of 71.626, indicating bullish momentum. However, the company reported a Q2 EPS of -$0.35, missing expectations, which poses a risk to investor confidence.
Valuation Metrics
The current forward P/E ratio for Janux Therapeutics Inc (JANX) is 0.00, compared to its 5-year average forward P/E of -13.94.
Alphio AI Price Scenarios for JANX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding JANX
Events Timeline
News
9.508-06seekingalphaJanux Therapeutics Q2 Earnings Miss Expectations
8.505-28Yahoo FinanceVERAXA Biotech Secures $27.5 Million Financing Agreement
6.505-23Yahoo FinanceProsight Management Increases Stake in Nektar Therapeutics
- 9.505-07seekingalpha
Janux Therapeutics Q1 Earnings Beat Expectations Despite Revenue Miss
8.504-27stocktwitsJanux Discontinues JANX008 Development to Focus on Other Pipeline Programs
JANX FAQ — answered by Alphio AI
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Janux Therapeutics Inc is a good buy right now due to its recent price increase of 8.62% over the last five days and a strong RSI of 71.626, indicating bullish momentum. However, the company reported a Q2 EPS of -$0.35, missing expectations, which poses a risk to investor confidence.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.